CL2009001012A1 - A method for treating a progesterone-dependent condition comprising the use of a composition comprising a 19-noresteroid antiprogestin containing a phenyl ring substituted with monomethylamine at the 11 beta position of the 11 carbon. - Google Patents

A method for treating a progesterone-dependent condition comprising the use of a composition comprising a 19-noresteroid antiprogestin containing a phenyl ring substituted with monomethylamine at the 11 beta position of the 11 carbon.

Info

Publication number
CL2009001012A1
CL2009001012A1 CL2009001012A CL2009001012A CL2009001012A1 CL 2009001012 A1 CL2009001012 A1 CL 2009001012A1 CL 2009001012 A CL2009001012 A CL 2009001012A CL 2009001012 A CL2009001012 A CL 2009001012A CL 2009001012 A1 CL2009001012 A1 CL 2009001012A1
Authority
CL
Chile
Prior art keywords
noresteroid
antiprogestin
monomethylamine
progesterone
carbon
Prior art date
Application number
CL2009001012A
Other languages
Spanish (es)
Inventor
Joseph S Podolski
Ronald D Wiehle
Original Assignee
Repros Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Repros Therapeutics Inc filed Critical Repros Therapeutics Inc
Publication of CL2009001012A1 publication Critical patent/CL2009001012A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Epidemiology (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Un método para el tratamiento de una condición dependiente de progesterona que comprende el uso de una composición que comprende una antiprogestina 19-noresteroide que contiene un anillo fenilo sustituido con monometilamina en la posición 11 beta del carbono 11.A method for the treatment of a progesterone-dependent condition comprising the use of a composition comprising a 19-noresteroid antiprogestin containing a phenyl ring substituted with monomethylamine at the 11 beta position of carbon 11.

CL2009001012A 2008-04-28 2009-04-28 A method for treating a progesterone-dependent condition comprising the use of a composition comprising a 19-noresteroid antiprogestin containing a phenyl ring substituted with monomethylamine at the 11 beta position of the 11 carbon. CL2009001012A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4845908P 2008-04-28 2008-04-28

Publications (1)

Publication Number Publication Date
CL2009001012A1 true CL2009001012A1 (en) 2009-09-25

Family

ID=40756776

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009001012A CL2009001012A1 (en) 2008-04-28 2009-04-28 A method for treating a progesterone-dependent condition comprising the use of a composition comprising a 19-noresteroid antiprogestin containing a phenyl ring substituted with monomethylamine at the 11 beta position of the 11 carbon.

Country Status (3)

Country Link
CL (1) CL2009001012A1 (en)
TW (1) TW201002736A (en)
WO (1) WO2009134725A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0900171A2 (en) * 2009-03-20 2010-12-28 Richter Gedeon Nyrt Novel crystal form of 17-acetoxy-11›-[4-(dimethyl-amino)-phenyl]-21-metoxy-19-norpregna-4,9-dien-3,20-dione and process for it's preparation
HUP0900487A2 (en) * 2009-08-05 2011-03-28 Richter Gedeon Nyrt 17-acetoxy-11ß-[4-(dimethyl-amino)-phenyl]-21-methoxy-19-norpregna-4,9-diene-3,20-dione new crystalline polymorphic modification and process for preparation
US9603856B2 (en) * 2013-11-03 2017-03-28 Flamina Holding Ag Pharmaceutical composition or group of compositions for inhibiting autocrine HCG production in adult human cells
RU2017112748A (en) 2014-11-17 2018-12-19 Арно Терапьютикс, Инк. ONAPRISTON COMPOSITIONS OF LONG-TERM ACTIONS AND METHODS
CA2998924A1 (en) 2015-09-25 2017-03-30 Context Biopharma Inc. Methods of making onapristone intermediates
CA3008422A1 (en) 2015-12-15 2017-06-22 Context Biopharma Inc. Amorphous onapristone compositions and methods of making the same
US20170266204A1 (en) * 2016-03-21 2017-09-21 Arno Therapeutics, Inc. Onapristone metabolite compositions and methods
US20180148471A1 (en) 2016-11-30 2018-05-31 Arno Therapeutics, Inc. Methods for onapristone synthesis dehydration and deprotection

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU710139B2 (en) * 1996-05-01 1999-09-16 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The 21-substituted progesterone derivatives as new antiprogestational agents
US6900193B1 (en) * 1996-05-01 2005-05-31 The United States Of America As Represented By The Department Of Health And Human Services Structural modification of 19-norprogesterone I: 17-α-substituted-11-β-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
AU4584901A (en) * 2000-03-17 2001-10-15 Us Gov Health & Human Serv Structural modification of 19-norprogesterone i: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents
US8173626B2 (en) * 2006-03-08 2012-05-08 Danco Laboratories Llc Methods, dosing regimens and medications using anti-progestational agents for the treatment of disorders
AU2007327707B2 (en) * 2006-10-24 2012-07-12 Allergan pharmaceuticals International Ltd. Compositions and methods for suppressing endometrial proliferation
PT2148681E (en) * 2007-04-20 2016-06-17 Preglem Sa Selective progesterone modulators in the treatment of uterine bleeding

Also Published As

Publication number Publication date
TW201002736A (en) 2010-01-16
WO2009134725A3 (en) 2009-12-23
WO2009134725A2 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
CL2009001012A1 (en) A method for treating a progesterone-dependent condition comprising the use of a composition comprising a 19-noresteroid antiprogestin containing a phenyl ring substituted with monomethylamine at the 11 beta position of the 11 carbon.
CO2020012824A2 (en) Substituted 4-aminoisoindoline-1,3-dione compounds and their use for the treatment of lymphoma
CO6321189A2 (en) BENCEN-SULFONAMIDE TIAZOL AND OXAZOL COMPOUNDS
CL2008002998A1 (en) Piperazine-1-carboxamide derived compounds, faah inhibitor; pharmaceutical composition comprising said compound; and use of the compound for the treatment of inflammatory or neuropathic pain, anxiety and depression.
CL2008002038A1 (en) Compounds derived from 3-phenyl-1,2-oxazole, sodium channel inhibitors; and its use for the treatment of a pain disorder.
CL2008002049A1 (en) Macrocyclic aminoindole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of hepatitis c.
CL2008001170A1 (en) Compounds derived from chromans and naphthalene substituted with a heterocyclic ring; pharmaceutical composition; and its use in the treatment of acute or chronic nociceptive pain or pain, visceral pain, inflammatory and / or central or peripheral neuropathic pain.
CL2007003202A1 (en) COMPOUNDS DERIVED FROM ESPIROINDOLINONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND FOR THE TREATMENT OF CELL PROLIFERATION DISORDERS.
HN2009001178A (en) 4-PHENYL-PIANO-3,5-DIONS, 4 PHENYL-THIOPIRANE-3,5-DIONS AND CYCLOHEXANETRIONS AS NEW HERBICIDES
CL2009000483A1 (en) Compounds derived from n- (pyridin-3-yl) -1,3-thiazole-5-amino-4-carboxamide, pim kinase inhibitors; pharmaceutical composition; and use for the treatment of cancer.
CL2008002295A1 (en) Alkylsulfonyl-substituted thiazolid derivative compounds; pharmaceutical composition; and use for the treatment of hepatitis c.
CL2011001497A1 (en) Compounds derived from heterocycles, gpr120 modulator; pharmaceutical composition; and its use for the treatment of type I, ii diabetes and metabolic syndrome.
SV2011003809A (en) HETEROARILO DERIVATIVES AS DGAT1 INHIBITORS
CL2012000033A1 (en) Compounds n- (3- (4as, 7as) -2-amino-4a, 5,7,7a-tetrahydro-4h-furo [3,4-d] [1,3] thiazin-7a-yl) -4- fluorophenyl) -5-fluoropiconylamide, bace inhibitor; pharmaceutical composition comprising them, use of the compound for the treatment of Alzheimer's disease.
CL2008001821A1 (en) Imidazo [2,1-b] -thiazole derived compounds; pharmaceutical composition comprising said compound; and use of the compound for the treatment of diabetes, metabolic syndrome, insulin resistance, among others.
NI201100108A (en) NEW PIRAZOLE - 4 - N - ALCOXICARBOXAMIDES AS MICROBICIDES.
CL2008002042A1 (en) Compounds derived from linked nitrogenous heterocycles; and its use in the treatment of diabetes and metabolic disorders.
CL2012000752A1 (en) Compounds derived from phenylpyri (mi) dinylpyrazoles for the control of unwanted microorganisms in the protection of plants and intermediate compounds.
CL2016001266A1 (en) New octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrol-2-yl.
CL2008000795A1 (en) USE OF 1- [2- (2,4-DIMETILFENILSULFANIL) PHENYL) PIPERAZINE FOR THE TREATMENT OF PAIN OR RESIDUAL SYMPTOMS OF DEPRESSION; AND SUCH COMPOUND.
CL2011000846A1 (en) Heterocyclic Substituted Compounds; pharmaceutical composition; and its use for the treatment of hepatitis c.
CL2008001560A1 (en) Nitrogen heterocycle derived compounds, gamma secretase modulators; pharmaceutical composition comprising them; and its use in the treatment of neurodegenerative diseases such as Alzheimer's, Down syndrome; pharmaceutical kit.
CL2008000202A1 (en) Compounds derived from n-aryl-acetamide, trpv1 antagonist, pharmaceutical composition that comprises them, useful in the treatment of pain.
PA8747701A1 (en) METHODS OF MARKING WITH RADIOACTIVE FLUOR
CL2008000110A1 (en) USE OF COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED FOR THE TREATMENT OF METABOLIC SYNDROME; AND COMPOUNDS DERIVED FROM PIRANONA SUBSTITUTED.